Transcode Therapeutics Inc (RNAZ) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Transcode Therapeutics Inc stock (RNAZ) is currently trading at $8.54. Analyst consensus price target for RNAZ is $10.00. WallStSmart rates RNAZ as Sell.
- RNAZ PE ratio analysis and historical PE chart
- RNAZ PS ratio (Price-to-Sales) history and trend
- RNAZ intrinsic value — DCF, Graham Number, EPV models
- RNAZ stock price prediction 2025 2026 2027 2028 2029 2030
- RNAZ fair value vs current price
- RNAZ insider transactions and insider buying
- Is RNAZ undervalued or overvalued?
- Transcode Therapeutics Inc financial analysis — revenue, earnings, cash flow
- RNAZ Piotroski F-Score and Altman Z-Score
- RNAZ analyst price target and Smart Rating
Transcode Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Transcode Therapeutics Inc (RNAZ) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Transcode Therapeutics Inc (RNAZ) Key Strengths (0)
Transcode Therapeutics Inc (RNAZ) Areas to Watch (4)
Company is destroying shareholder value
Very expensive at 5.7x book value
Very low institutional interest at 5.67%
Micro-cap company with very limited liquidity and high volatility
Transcode Therapeutics Inc (RNAZ) Detailed Analysis Report
Overall Assessment
This company scores 6/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 0 register as strengths (avg 0/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Price/Book, Institutional Own.. Some valuation metrics including Price/Book (5.69) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -1763.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -1763.00% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RNAZ Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WallStSmart Analysis Synopsis
Data-driven financial summary for Transcode Therapeutics Inc (RNAZ) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Transcode Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Free cash flow is -4M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.54, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Transcode Therapeutics Inc.
Bottom Line
Transcode Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Transcode Therapeutics Inc(RNAZ)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
TransCode Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development and commercialization of drugs for the treatment of metastatic diseases. The company is headquartered in Boston, Massachusetts.